AMCP Nexus: The Academy of Managed Care Pharmacy Nexus

Speakers at AMCP Nexus 2025 reviewed the oncology pipeline, highlighting expanded indications and new therapies advancing innovation, access, and value.

AMCP Nexus connects pharmacy leaders, drives policy change, and empowers members to enhance health care access and improve patient outcomes.

Kimberly Westrich, MA, discusses how patient engagement can revolutionize health care decision-making and break down barriers to accessing necessary medicines and care.

Innovative payer approaches and holistic support could help expand GLP-1 use and improve obesity care outcomes, experts claimed.

PBM legislation is rising nationwide, which experts emphasize could increase costs and hinder patient care.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Harry Travis, BS Pharm, MBA, explores how artificial intelligence (AI) can revolutionize pharmacy workflows for sustainable productivity gains.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

Brigid Groves, PharmD, MS, discusses the importance of using trustworthy sources so that pharmacists can support communities with accurate information.

Real-world evidence helps pharmaceutical companies and payers communicate more effectively.

Chelsea Renfro, PharmD, discusses the importance of rigorous study designs to establish medication efficacy.

The antiretroviral (ART) regimen Biktarvy showed higher 1-year ART persistence and lower switch rates among people with HIV.

In the midst of a government shutdown, former House Speaker Paul Ryan urges clear policies, AI innovation, and patient-focused solutions to build a sustainable US health care system.

Posters presented at AMCP Nexus 2025 found especially low oral HIV PrEP uptake among transgender individuals and those facing insurance challenges.

The AMCP Nexus 2025 conference will bring together professionals to discuss drug access and policy, as well as the future of pharmacy.

Susan Cantrell, CEO of the Academy of Managed Care Pharmacy, shares exclusive insights on key themes that will be discussed at this year's Nexus conference.

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.

The US could start catching up to Europe on biosimilars if the FDA removed the need for switching studies to be granted interchangeability.

New legislation would clarify rules around value-based contracts in Medicaid, and a new model is expanding access to gene therapies, explained Adam Colborn, JD, of AMCP.

CMS is creating infrastructure to improve coverage of prescription digital therapeutics (PDTs), and new legislation would also drive uptake of PDTs.

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

Caregivers of both adults and children with Duchenne muscular dystrophy (DMD) face significant disruptions to their work productivity and personal lives, underscoring the need for better treatments and support systems.

Cost avoidance varied by clinical setting, with the largest savings occurring in hematology clinics ($73,773), followed by rheumatology ($45,330) and pediatric gastrointestinal/irritable bowel syndrome ($16,519).

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients.

Kimberly Westrich, MA, of National Pharmaceutical Council, and Adam Colborn, JD, of AMCP, run through the current status of lawsuits and lawmaking at the federal and state levels related to pharmacy benefit managers and cost-shifting programs.

In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.

The AMCP Nexus 2024 annual meeting covered a variety of hot health care topics impacting managed care pharmacy in the present and future.

While treatment options are evolving cancer care and extending lifespans, there is still a lack of biomarkers in certain cancers that can help direct treatment or provide early detection.

Experts explored the potential impacts of a Trump or Harris administration on the future of health care.